BioNexus Gene Lab Taps ML Tech for AI-Driven Ethereum Growth

BioNexus Gene Lab Corp. (BGLC), a technology-driven innovator in digital and healthcare sectors, has announced a strategic partnership with ML Tech, an AI-powered wealth management platform for digital assets. Regulated by the National Futures Association (NFA) and headquartered in Miami, ML Tech will help optimize BGLC’s Ethereum-based treasury strategy.

By leveraging ML Tech’s institutional-grade trading infrastructure, BGLC aims to enhance its Ethereum holdings while maintaining liquidity and security. ML Tech specializes in delta-neutral and market-neutral strategies, providing advanced quantitative investment solutions designed to maximize returns while mitigating risk.

“We are excited to collaborate with BioNexus Gene Lab Corp to bring our innovative Ethereum yield strategies to their treasury operations,” said Leo Mindyuk, CEO and CIO of ML Tech. “Our non-custodial execution model ensures full transparency and security while optimizing asset growth.”

BGLC’s Ethereum treasury strategy aligns with its commitment to blockchain innovation and long-term shareholder value. “Partnering with ML Tech allows us to leverage AI-driven trading expertise to enhance efficiency and performance in our treasury operations,” said Sam Tan, CEO of BioNexus Gene Lab Corp.

This partnership signals BGLC’s intent to integrate blockchain technologies into its financial ecosystem, unlocking new opportunities in digital asset management. With ML Tech’s expertise in low-correlation trading strategies, BGLC is positioned to navigate the evolving cryptocurrency landscape with confidence.